Phase I study of topotecan and radiation therapy in advanced cervical cancer

Charles J. Dunton, Stephanie A. King, Julia Neufeld, Jorge Tolosa, Gonzalo Perez, Andres Avila, Kelly Underhill

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective. The goal of this study was to determine the maximal tolerated dose (MTD) of topotecan given with external-beam radiotherapy in advanced cervical cancer. Methods. A prospective Phase I trial of topotecan given with standard external-beam radiotherapy was performed in patients with advanced squamous cell carcinoma of the cervix. Patients were treated with a starting dose of 0.5 mg/m2 and escalated by 0.25 mg/m2. Nine patients were treated. Hematologic and nonhematologic toxicity were measured. Results. Patients were treated with 1.0 mg/m2 daily for 5 days on Days 1-5 and 22-26 concomitantly with radiotherapy without significant toxicity. Grade III anemia in one case and Grade II leukopenia in two cases were seen in the three patients at this dose level. Dose-limiting toxicity was not reached. Conclusion. Topotecan can be safely administered at a dose of 1.0 mg/m2 during external-beam radiotherapy for advanced cervical cancer.

Original languageEnglish (US)
Pages (from-to)185-187
Number of pages3
JournalGynecologic Oncology
Volume85
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Topotecan
Uterine Cervical Neoplasms
Radiotherapy
Maximum Tolerated Dose
Leukopenia
Cervix Uteri
Anemia
Squamous Cell Carcinoma

Keywords

  • Radiation sensitization
  • Squamous cell carcinoma of the cervix
  • Topotecan

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Dunton, C. J., King, S. A., Neufeld, J., Tolosa, J., Perez, G., Avila, A., & Underhill, K. (2002). Phase I study of topotecan and radiation therapy in advanced cervical cancer. Gynecologic Oncology, 85(1), 185-187. https://doi.org/10.1006/gyno.2002.6609

Phase I study of topotecan and radiation therapy in advanced cervical cancer. / Dunton, Charles J.; King, Stephanie A.; Neufeld, Julia; Tolosa, Jorge; Perez, Gonzalo; Avila, Andres; Underhill, Kelly.

In: Gynecologic Oncology, Vol. 85, No. 1, 2002, p. 185-187.

Research output: Contribution to journalArticle

Dunton, CJ, King, SA, Neufeld, J, Tolosa, J, Perez, G, Avila, A & Underhill, K 2002, 'Phase I study of topotecan and radiation therapy in advanced cervical cancer', Gynecologic Oncology, vol. 85, no. 1, pp. 185-187. https://doi.org/10.1006/gyno.2002.6609
Dunton, Charles J. ; King, Stephanie A. ; Neufeld, Julia ; Tolosa, Jorge ; Perez, Gonzalo ; Avila, Andres ; Underhill, Kelly. / Phase I study of topotecan and radiation therapy in advanced cervical cancer. In: Gynecologic Oncology. 2002 ; Vol. 85, No. 1. pp. 185-187.
@article{4c697b7510a842f1bf2e5bb7ead0419d,
title = "Phase I study of topotecan and radiation therapy in advanced cervical cancer",
abstract = "Objective. The goal of this study was to determine the maximal tolerated dose (MTD) of topotecan given with external-beam radiotherapy in advanced cervical cancer. Methods. A prospective Phase I trial of topotecan given with standard external-beam radiotherapy was performed in patients with advanced squamous cell carcinoma of the cervix. Patients were treated with a starting dose of 0.5 mg/m2 and escalated by 0.25 mg/m2. Nine patients were treated. Hematologic and nonhematologic toxicity were measured. Results. Patients were treated with 1.0 mg/m2 daily for 5 days on Days 1-5 and 22-26 concomitantly with radiotherapy without significant toxicity. Grade III anemia in one case and Grade II leukopenia in two cases were seen in the three patients at this dose level. Dose-limiting toxicity was not reached. Conclusion. Topotecan can be safely administered at a dose of 1.0 mg/m2 during external-beam radiotherapy for advanced cervical cancer.",
keywords = "Radiation sensitization, Squamous cell carcinoma of the cervix, Topotecan",
author = "Dunton, {Charles J.} and King, {Stephanie A.} and Julia Neufeld and Jorge Tolosa and Gonzalo Perez and Andres Avila and Kelly Underhill",
year = "2002",
doi = "10.1006/gyno.2002.6609",
language = "English (US)",
volume = "85",
pages = "185--187",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Phase I study of topotecan and radiation therapy in advanced cervical cancer

AU - Dunton, Charles J.

AU - King, Stephanie A.

AU - Neufeld, Julia

AU - Tolosa, Jorge

AU - Perez, Gonzalo

AU - Avila, Andres

AU - Underhill, Kelly

PY - 2002

Y1 - 2002

N2 - Objective. The goal of this study was to determine the maximal tolerated dose (MTD) of topotecan given with external-beam radiotherapy in advanced cervical cancer. Methods. A prospective Phase I trial of topotecan given with standard external-beam radiotherapy was performed in patients with advanced squamous cell carcinoma of the cervix. Patients were treated with a starting dose of 0.5 mg/m2 and escalated by 0.25 mg/m2. Nine patients were treated. Hematologic and nonhematologic toxicity were measured. Results. Patients were treated with 1.0 mg/m2 daily for 5 days on Days 1-5 and 22-26 concomitantly with radiotherapy without significant toxicity. Grade III anemia in one case and Grade II leukopenia in two cases were seen in the three patients at this dose level. Dose-limiting toxicity was not reached. Conclusion. Topotecan can be safely administered at a dose of 1.0 mg/m2 during external-beam radiotherapy for advanced cervical cancer.

AB - Objective. The goal of this study was to determine the maximal tolerated dose (MTD) of topotecan given with external-beam radiotherapy in advanced cervical cancer. Methods. A prospective Phase I trial of topotecan given with standard external-beam radiotherapy was performed in patients with advanced squamous cell carcinoma of the cervix. Patients were treated with a starting dose of 0.5 mg/m2 and escalated by 0.25 mg/m2. Nine patients were treated. Hematologic and nonhematologic toxicity were measured. Results. Patients were treated with 1.0 mg/m2 daily for 5 days on Days 1-5 and 22-26 concomitantly with radiotherapy without significant toxicity. Grade III anemia in one case and Grade II leukopenia in two cases were seen in the three patients at this dose level. Dose-limiting toxicity was not reached. Conclusion. Topotecan can be safely administered at a dose of 1.0 mg/m2 during external-beam radiotherapy for advanced cervical cancer.

KW - Radiation sensitization

KW - Squamous cell carcinoma of the cervix

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0036223141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036223141&partnerID=8YFLogxK

U2 - 10.1006/gyno.2002.6609

DO - 10.1006/gyno.2002.6609

M3 - Article

VL - 85

SP - 185

EP - 187

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -